Perspectives on the therapeutic potential of short-chain fatty acid receptors.

Abstract

There is rapidly growing interest in the human microbiome because of its implication in metabolic disorders and inflammatory diseases. Consequently, understanding the biology of short chain fatty acids and their receptors has become very important for identifying novel therapeutic avenues. GPR41 and GPR43 have been recognized as the cognate receptors for SCFAs and their roles in metabolism and inflammation have drawn much attention in recent years. GPR43 is highly expressed on immune cells and has been suggested to play a role in inflammatory diseases such as inflammatory bowel disease. Both GPR41 and GPR43 have been implicated in diabetes and obesity via the regulation of adipose tissue and gastrointestinal hormones. So far, many studies have provided contradictory results, and therefore further research is required to validate these receptors as drug targets. We will also discuss the synthetic modulators of GPR41 and GPR43 that are critical to understanding the functions of these receptors.

• Authors: Sunhong Kim, Jeong-Hoon Kim, Bi Oh Park, Young Shin Kwak
• Journal: BMB reports (BMB Rep) Vol. 47 Issue 3 Pg. 173-8 (Mar 2014) ISSN: 1976-670X [Electronic] Korea (South)
• PMID: 24499669 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)

Chemical References

• Fatty Acids, Volatile
• Receptors, G-Protein-Coupled

Topics

• Animals
• Fatty Acids, Volatile (metabolism)
• Humans
• Molecular Targeted Therapy
• Receptors, G-Protein-Coupled (agonists, antagonists & inhibitors, metabolism, therapeutic use)